Learn About Gastroesophageal Junction Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Rhode Island Hospital
Howard Safran is a Hematologist Oncology specialist and a Hematologist in Providence, Rhode Island. Dr. Safran and is rated as an Elite provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Pancreatic Cancer, Gastroesophageal Junction Cancer, Colorectal Cancer, Neuroendocrine Tumor, and Pancreaticoduodenectomy.
Duke Health Integrated Practice Inc
Hope Uronis is an Oncologist in Durham, North Carolina. Dr. Uronis and is rated as an Elite provider by MediFind in the treatment of Gastroesophageal Junction Cancer. Her top areas of expertise are Gastroesophageal Junction Cancer, Colorectal Cancer, Pancreatic Cancer, Stomach Cancer, and Pancreaticoduodenectomy. Dr. Uronis is currently accepting new patients.
Eric Van Cutsem practices in Leuven, Belgium. Mr. Van Cutsem and is rated as an Elite expert by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Colorectal Cancer, Gastroesophageal Junction Cancer, Stomach Cancer, Hepato-Pancreato-Biliary Surgery, and Endoscopy.
Summary: Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a protein on a type of immune cell called a T-cell. This tells the immune system to attack the tumor. ASP2138 is a potential treatment for people with stomach can...
Summary: This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or ...